Dr. Tomer Berkovitz is a General Partner at aMoon. As a former investment banker and senior executive in public companies, Tomer witnessed how the sectors of healthcare and technology were converging into a new industry that had the potential to make a global impact.
Since joining aMoon in February 2018, Tomer has led investments and served on the board of directors of several HealthTech companies, including Seer (NASDAQ:SEER), SOPHiA GENETICS (NASDAQ: SOPH), Sera Prognostics (NASDAQ: SERA), PrognomIQ, Zebra Medical Vision (acquired by Nanox, NASDAQ: NNOX), Omada Health, and others.
Tomer started his Wall Street career as an investment banker at J.P. Morgan in New York, where he led HealthCare in its Corporate Finance Advisory team. In this position, he played a key role in numerous capital market transactions and mergers and acquisitions. After J.P. Morgan, Tomer was appointed CFO & COO of Alcobra, a NASDAQ-listed biopharmaceutical company, where he led public equity offerings and its merger with Arcturus Therapeutics.
Tomer earned his Ph.D. in Finance (with Distinction) from Columbia Business School and published his research work in leading academic and practitioner journals. He also holds a B.A. in Economics and Management (Magna Cum Laude) and M.Sc. in Finance and Accounting (Magna Cum Laude), both from Tel Aviv University.